Literature DB >> 11063834

Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis.

S H Im1, D Barchan, S Fuchs, M C Souroujon.   

Abstract

Acetylcholine receptor (AChR) is the major autoantigen in myasthenia gravis (MG) and experimental autoimmune MG (EAMG). Here we analyze the mechanisms involved in suppression of ongoing EAMG in rats by nasal administration of a recombinant fragment from the human AChR alpha-subunit. We demonstrate that such a fragment, expressed without a fusion partner, confers nasal tolerance that can be adoptively transferred. Our observations suggest that the underlying mechanism of this nasal tolerance is active suppression involving a shift from a Th1 to a Th2/Th3-regulated AChR-specific response which may be mediated by down regulation of costimulatory factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063834     DOI: 10.1016/s0165-5728(00)00395-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN.

Authors:  Poh-Yi Gan; Diana S Y Tan; Joshua D Ooi; Maliha A Alikhan; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

Review 3.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

4.  Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.

Authors:  Jon Lindstrom; Jie Luo; Alexander Kuryatov
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

5.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Authors:  Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

6.  Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis.

Authors:  John Reynolds; Danielle S Abbott; Julieta Karegli; David J Evans; Charles D Pusey
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

7.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570

8.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

9.  A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.

Authors:  Alessandra Consonni; Sapna Sharma; Karin Schön; Cristina Lebrero-Fernández; Elena Rinaldi; Nils Yngve Lycke; Fulvio Baggi
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

10.  MuSK EAMG: Immunological Characterization and Suppression by Induction of Oral Tolerance.

Authors:  Debby Reuveni; Revital Aricha; Miriam C Souroujon; Sara Fuchs
Journal:  Front Immunol       Date:  2020-03-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.